Simulations Plus

For a generic drug, the objective is to develop a formulation/process that would result in the product performance equivalent to that of the reference (innovative) product throughout the product life-cycle.

Every lead compound that enters preclinical testing warrants some form of noncompartmental analysis (NCA), with promising candidates that are heading into clinical trials requiring validated NCA as part...

This webinar will focus on 2 case studies from scientists from Roche and Janssen describing the use of GastroPlus PBPK modeling to eliminate bridging clinical studies.

The user interface in ADMET Predictor was completely rewritten for version 8. In this webinar, we demonstrate the new tools available in ADMET Predictor 8 using examples from various data sets, e.g., BACE1 inhibitors.

In this webinar, case studies will be presented highlighting the use of DDDPlus and GastroPlus to optimize formulations and apply virtual 'lot-to-lot' variability effects to help establish dissolution specifications.

This webinar will focus on the description of a novel mechanistic mathematical model developed to describe in vitro dissolution and precipitation data and how the model can be used in a wider PBPK framework...

In this GastroPlus™ User Group webinar, we will discuss the validation of passive permeability estimates in MembranePlus™ based on molecular structure alone for a library of diverse compounds and how...

This GastroPlus™ User Group video explores how the ACAT model, with customized refinement of the model parameters or design of the model structure, can provide valuable insights to address various aspects of...

This video explores analyzing the structural sensitivity of QSAR models using matched molecular pairs using MedChem Studio™

This GastroPlus™ User Group webinar will focus on special considerations when performing pediatric PBPK modeling in GastroPlus™.

Two new models, fraction unbound to liver microsomes and unbound human liver microsomal intrinsic clearance, were added to ADMET Predictor 7.2.

This informative webinar covers the new features in the latest version of GastroPlus™ 9.0.

This GastroPlus™ User Group webinar explores human exposure predictions and food effect risk identification using preclinical data and PBPK models.

In this presentation, Dr. Eric Martin of Novartis discusses improving bioavailability during lead optimization using global sensitivity analysis (GSA) of physiologically based pharmacokinetics.

In this webinar Dr. Stephen Ferguson of the National Institutes of Environmental Health Sciences discusses in silico approaches to predict human xenobiotic metabolism and their potential for human toxicity.

Learn about the new features in GastroPlus 8.6, how to build custom PBPK models for different disease states, and see a teaser of what's coming in version 9.0.

In this video, Dr. Viera Lukacova discusses how to get the most out of your in vitro permeability assays with MembranePlus™.

This video shows how MedChem Studio™ can be used to analyze percent inhibition data from a high-throughput screening experiment in order to identify candidates for further optimization.

This webinar is presented to provide details and answer questions concerning Simulations Plus' acquisition of Cognigen Corporation.